Medication info

CAPD 4 Balance Peritoneal Dialysis Solution

Prescription medicationSolutionInjection
Ingredient · strength
Sodium Chloride›11.279gCalcium Chloride Hydrate›0.5145gMagnesium Chloride Hexahydrate›0.2033gGlucose Hydrate›50gSodium Lactate 50%›15.69g
Manufacturer / importer
Fresenius Medical Care Korea Ltd.
Appearance
Colorless, transparent solution divided into two liquids: Solution A (left) and Solution B (right) in a λ shape.
Packaging
100/box [1,500mL x 1, 2,000mL x 1, 2,500mL x 1, 3,000mL x 1], 400/box [2,000mL x 4, 2,500mL x 4, 3,000mL x 4], 600/box [1,500mL x 6]
Approval status
Active

MFDS item code 200009100 · Notified 2000.07.21 · Insurance code 664300360,664300370,664300380,664300390

Summary

Main use
Peritoneal dialysis treatment in patients with acute or chronic renal failure
Who receives it
Adults
Adult administration
1. The attending physician should adjust the treatment method, number of procedures, exchange volume, dialysis time, and duration according to the patient’s condition. 2. Use as a solution for intraperitoneal administration for dialysis treatment. 3. The dose varies according to body size, and the frequency of solution exchanges should be adjusted appropriately based on biochemical parameters and fluid volume control. In adults, the usual procedure is to instill 1.5~2.5L into the peritoneal cavity per exchange, allow it to dwell for 4~8 hours, and then drain it; this process is performed 3~5 times daily. 4. If a machine is used intermittently or continuously for peritoneal dialysis, it is preferable to use a bag with a volume greater than the machine’s exchange volume. 5. The glucose concentration should be selected according to the patient’s ultrafiltration needs and kept as low as possible.

Ingredients

Importer
Fresenius Medical Care Korea Ltd.

Efficacy & effects

Peritoneal dialysis treatment in patients with acute or chronic renal failure

View approved original text

This medication is used for peritoneal dialysis in patients with acute and chronic renal failure. It helps improve health by removing waste products and excess fluid from the body when kidney function is not operating normally.

How it is given

Adult administration

1. The attending physician should adjust the treatment method, number of procedures, exchange volume, dialysis time, and duration according to the patient’s condition. 2. Use as a solution for intraperitoneal administration for dialysis treatment. 3. The dose varies according to body size, and the frequency of solution exchanges should be adjusted appropriately based on biochemical parameters and fluid volume control. In adults, the usual procedure is to instill 1.5~2.5L into the peritoneal cavity per exchange, allow it to dwell for 4~8 hours, and then drain it; this process is performed 3~5 times daily. 4. If a machine is used intermittently or continuously for peritoneal dialysis, it is preferable to use a bag with a volume greater than the machine’s exchange volume. 5. The glucose concentration should be selected according to the patient’s ultrafiltration needs and kept as low as possible.

Precautions

This medication is a dialysis solution for peritoneal dialysis and is used in patients with impaired kidney function. Prompt discontinuation of peritoneal dialysis may pose a risk to life if the patient does not receive other kidney replacement therapies, thus caution is required. Certain patient populations are prohibited from using this drug; for example, patients with diaphragmatic defects, abdominal burns, severe peritoneal adhesions, and high risk of bleeding should not use this medication. Patients suspected of having lactate metabolism disorders or having severe electrolyte imbalances, as well as those who have recently undergone abdominal surgery, should also avoid administration of this drug. Additionally, patients with peritonitis or sepsis, those with severe pulmonary disease, and patients experiencing significant weight loss should be administered this drug cautiously and strictly according to a physician's directives. During administration, various adverse reactions such as abdominal pain, bleeding, peritonitis, electrolyte imbalance, gastrointestinal symptoms, and dyspnea may occur, so careful monitoring is necessary. Particularly, due to the possibility of peritonitis, aseptic conditions must be maintained during administration and it should be used in a clean environment. During dialysis, weight, serum electrolyte levels, blood sugar, and protein levels should be checked regularly to prevent abnormalities. This medication may interact with other drugs; therefore, if the patient is taking other medications, it is mandatory to consult with healthcare professionals. Pregnant or nursing women should assess the need and risk since the safety of this drug has not been established. Special attention and dosage adjustments are required for children and the elderly, and there is a risk of dehydration, electrolyte abnormalities, and hyperglycemia in cases of overdose. The peritoneal dialysis solution should be used as provided in the container, and it should not be used if the packaging is damaged or if the solution is cloudy. Always check the condition of the solution before use, and it is intended for intraperitoneal dialysis only; it should not be used as an injection. This drug should be kept away from direct sunlight and freezing, stored at room temperature, and any remaining solution should not be reused. When adding medications, ensure aseptic handling and use immediately after addition. To safely perform peritoneal dialysis, administration should be under medical supervision, and if the patient performs dialysis independently, sufficient education and training are necessary.

Side effects

Abdominal pain, bleeding, peritonitis, abdominal discomfort, cloudy drainage, fever, inflammation around the abdominal catheter, erythema, discharge, catheter rupture, subcutaneous inflammation at the drainage difficulty site, nausea, diarrhea, constipation, hemorrhoids, vomiting, loss of appetite, abdominal distension, intestinal obstruction, hypokalemia, hyponatremia, hypercalcemia, hypophosphatemia, hyperlactatemia, hypomagnesemia, hypercholesterolemia, hypertriglyceridemia, metabolic acidosis, hypoproteinemia, hyperglycemia, respiratory distress due to diaphragm elevation, respiratory symptoms related to electrolyte disorders, pulmonary edema, pleural effusion, edema, amino acid loss, water-soluble vitamin loss, shoulder pain, fever, muscle cramps, hernia, hydrocele, obesity, frailty, syncope, fatigue, headache, dizziness, tachycardia, hypertension, hypotension, sclerosing encapsulating peritonitis, sepsis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container and kept at a temperature below 25 degrees Celsius. Additionally, care should be taken to prevent the drug from freezing.

Appearance and packaging

Appearance

Colorless, transparent solution divided into two liquids: Solution A (left) and Solution B (right) in a λ shape.

Package unit

100/box [1,500mL x 1, 2,000mL x 1, 2,500mL x 1, 3,000mL x 1], 400/box [2,000mL x 4, 2,500mL x 4, 3,000mL x 4], 600/box [1,500mL x 6]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.